The fund will be used by Glytec to advance research and development, increase its international presence and diverse its direct US sales force.
Glytec develops real-time glycemic management systems for individualized dosage recommendations of insulin, glucose and saline.
The company will also consider all pertinent patient information such as demographics, lab results, and risk factors.
